Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab for Primary Sclerosing Cholangitis with IBD
NCT03035058Phase 3Withdrawn
- Sponsor
- Takeda
- Start
- Feb 2017
- Primary completion
- Sep 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 3, randomised, double-blind trial of vedolizumab in Primary Sclerosing Cholangitis (PSC) (3 arms), sponsored by Takeda. Primary endpoint: Percentage of Participants with No Worsening in Ishak Fibrosis Staging Score from Baseline to Week 106 Visit. Planned start Feb 2017; status: withdrawn.
02
Drugs
vedolizumab
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on NCT03035058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03035058.